Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 임우성 | - |
dc.date.accessioned | 2024-02-15T05:11:51Z | - |
dc.date.available | 2024-02-15T05:11:51Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.other | OAK-34354 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/267782 | - |
dc.description.abstract | PURPOSETo determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial.PATIENTS AND METHODSThis study is a post-trial follow-up of the ASTRRA trial, involving 1,483 premenopausal women younger than 45 years treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy for estrogen receptor-positive breast cancer. Patients were randomly assigned in a 1:1 ratio to complete 5 years of tamoxifen (TAM) alone (TAM-only) or 5 years of TAM with ovarian function suppression (OFS) for 2 years (TAM + OFS). The primary end point was disease-free survival (DFS), and the secondary end point was overall survival (OS).RESULTSAt 106.4 months of median follow-up, there was a continuous significant reduction in the DFS event rate in the TAM + OFS group. The 8-year DFS rate was 85.4% in the TAM + OFS group and 80.2% in the TAM-only group (hazard ratio [HR], 0.67; 95% CI, 0.51 to 0.87). There were no significant differences in OS between the two groups. The OS rate was 96.5% in the TAM + OFS group and 95.3% in the TAM-only group (HR, 0.78; 95% CI, 0.49 to 1.25).CONCLUSIONAdding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy. © American Society of Clinical Oncology. | - |
dc.language | English | - |
dc.publisher | Lippincott Williams and Wilkins | - |
dc.title | Adding Ovarian Suppression to Tamoxifen for Premenopausal Women with Hormone Receptor-Positive Breast Cancer after Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial | - |
dc.type | Article | - |
dc.relation.issue | 31 | - |
dc.relation.volume | 41 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 4864 | - |
dc.relation.lastpage | 4871 | - |
dc.relation.journaltitle | Journal of Clinical Oncology | - |
dc.identifier.doi | 10.1200/JCO.23.00557 | - |
dc.identifier.wosid | WOS:001096174500007 | - |
dc.identifier.scopusid | 2-s2.0-85175357595 | - |
dc.author.google | Eunhwa | - |
dc.author.google | Sung Yong | - |
dc.author.google | Min Hyuk | - |
dc.author.google | Lee Su | - |
dc.author.google | Lim | - |
dc.author.google | Woosung | - |
dc.author.google | Seonok | - |
dc.author.google | Hee Jeong | - |
dc.author.google | Baek | - |
dc.author.google | Soo Yeon | - |
dc.author.google | Noh | - |
dc.author.google | Woo Chul | - |
dc.author.google | Ahn | - |
dc.author.google | Sei-Hyun | - |
dc.author.google | Kim | - |
dc.author.google | Hyun-Ah | - |
dc.author.google | Ryu | - |
dc.author.google | Jai Min | - |
dc.author.google | Seung Il | - |
dc.author.google | Lee | - |
dc.author.google | Eun-Gyeong | - |
dc.author.google | Im | - |
dc.author.google | Seock-Ah | - |
dc.author.google | Jung | - |
dc.author.google | Yongsik | - |
dc.author.google | Park | - |
dc.author.google | Min Ho | - |
dc.author.google | Kyong Hwa | - |
dc.author.google | Kang | - |
dc.author.google | Su Hwan | - |
dc.author.google | Jeong | - |
dc.author.google | Joon | - |
dc.contributor.scopusid | 임우성(27167744500) | - |
dc.date.modifydate | 20240208145502 | - |